Axonal transport—the bidirectional movement of cargo along microtubule tracks via kinesin and dynein motor proteins—is a fundamental neuronal process that declines sharply in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and Huntington's disease (HD). Disrupted axonal transport causes accumulation of mitochondria, synaptic vesicles, neurotrophic factors, and signaling endosomes in the soma, leading to synaptic failure, axonal degeneration, and eventual neuronal death. This therapy targets the molecular machinery of axonal transport for rescue and restoration.
Neurons rely on microtubule-based axonal transport for all long-range intracellular logistics. Two major motor protein families drive this process:
Kinesin superfamily (KIFs): Primarily responsible for anterograde transport (soma to axon terminal). Kinesin-1 (KIF5A/KIF5C), kinesin-3 (KIF1A/KIF1B), and kinesin-2 (KIF17) carry synaptic vesicle precursors, mitochondria, protein complexes, and RNA granules. [@giao2019]
Cytoplasmic dynein-1 with dynactin complex: Responsible for retrograde transport (axon terminal to soma). Dynein carries neurotrophic endosomes, signaling complexes, mitochondrial quality-control cargoes, and autophagosomes. The dynactin complex (p150^Glued/DCTN1, p62, Arp1) is essential for dynein processivity and cargo attachment. [1]
The coordinated activity of both systems is essential for synaptic function, axonal maintenance, and neuronal survival.
Multiple disease proteins directly disrupt axonal transport at multiple levels:
Tau (hyperphosphorylated in AD/PSP/CBD): Tau displaces kinesin and dynein from microtubule binding sites, competitively blocking motor attachment. p-Tau S262 and S356 directly reduce kinesin processivity by 60-80%. Tau also mislocalizes dynein to the soma, severing retrograde signaling.
Alpha-synuclein (in PD/DLB/MSA): Oligomeric alpha-synuclein binds directly to kinesin light chain, inhibiting its ATPase activity and blocking anterograde transport. Alpha-synuclein also disrupts dynein-dynactin complex formation, impairing retrograde flow.
TDP-43 (in ALS/FTD): TDP-43 aggregates sequester dynein/dynactin components in the cytoplasm, causing a dominant-negative blockade of retrograde transport. TDP-43 mislocalization is found in >95% of ALS cases and ~50% of frontotemporal dementia cases.
Huntingtin (mutant in HD): Mutant huntingtin directly binds to HAP1 (huntingtin-associated protein 1) and p150^Glued/dynactin, disrupting the dynein-dynactin interaction and causing perinuclear cargo accumulation.
SOD1/G case causative mutations: Disrupt mitochondrial transport coordination through altered Milton/GRIF1 interaction with kinesin-1. [2]
Axonal transport deficits precede clinical symptoms in most neurodegenerative disease models:
Transport defects trigger a cascade: reduced neurotrophic factor delivery → synaptic loss → axonal swelling → organelle accumulation → axonal fragmentation → neuronal death. [3]
Rationale: Hyperphosphorylated tau reduces kinesin attachment to microtubules. Small molecules that restore kinesin binding to microtubules (without competing with tau) can re-establish anterograde transport.
Approach:
Target compounds: Nufinostat (CDK5 inhibitor, CNS-penetrant), Kinesin-1 agonist compounds identified in high-content screening (HCS) of FDA-approved library. [4]
Validation Evidence:
Rationale: Dynein processivity depends critically on the dynactin complex. Mutations in DCTN1 (p150^Glued) and other dynactin subunits reduce dynein processivity by 40-70%, causing perinuclear cargo accumulation. Stabilizing the dynactin complex can restore retrograde transport.
Approach:
Target compounds: Dynactin-stabilizing peptides (based on DCTN1 structural studies), small molecules identified via cryo-EM-guided drug design targeting the p150^Glued coiled-coil domain. [5]
Validation Evidence:
Rationale: Acetylated microtubules (at K40 of alpha-tubulin) support more efficient kinesin-1 transport. HDAC6 (histone deacetylase 6) deacetylates microtubules, and HDAC6 inhibitors (tubastatin A, ACY-1215) restore acetylation, improving transport velocity.
Approach:
Synergy: HDAC6 inhibition simultaneously enhances axonal transport (via microtubule acetylation) and autophagy (via aggresome-autophagy pathway), making it a high-value combination target.
Validation Evidence:
Rationale: Mitochondrial transport is mediated by Milton (Miro1/TRAK1/TRAK2 in humans) which links mitochondria to kinesin-1 and dynein. Calcium influx (through NMDAR or VGCC) triggers Miro1 degradation, arresting mitochondrial transport. In neurodegeneration, chronic calcium dysregulation causes Miro1 loss.
Approach:
Biomarker: CSF Miro1/Miro2 ratio as pharmacodynamic marker of mitochondrial transport rescue.
Rationale: Gene delivery of wild-type KIF5A or KIF1A can compensate for transport deficits caused by mutations or disease-related impairment. AAV9-mediated delivery to motor neurons targets both upper and lower motor neurons (relevant for ALS).
Approach:
Evidence: KIF5A overexpression in SOD1^G93A mice extends survival by 15-20 days and reduces motor neuron loss. AAV-KIF1A delivery in KIF1A knockout mice partially rescues motor deficits. [6]
Validation Evidence:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Kinesin-dynein coordination is well-studied but targeted therapy is underexplored. Most efforts focus on tau or alpha-synuclein directly, not the transport machinery itself. Multi-motor coordination therapy is genuinely novel. |
| Mechanistic Rationale | 9 | Axonal transport deficits are causally linked to neuronal death (genetic evidence from KIF5A, KIF1A, DCTN1 mutations). Disease proteins (tau, alpha-syn, TDP-43) all converge on transport disruption. Mechanism is well-established and druggable. |
| Root-Cause Coverage | 8 | Addresses a proximal cause of neuronal dysfunction rather than downstream inflammation. Transport deficits precede clinical symptoms and synaptic loss in multiple models. |
| Delivery Feasibility | 6 | Small molecules face BBB (molecular weight <400 Da needed). AAV approaches face CNS delivery efficiency challenges. Peptide delivery via TAT sequences is emerging. HDAC6 inhibitors (tubastatin A) already cross BBB. |
| Safety Plausibility | 7 | Kinesin/dynein are essential but have tissue-specific isoforms. Selective targeting to neuronal kinesin-1 (KIF5A/C) sparing kinesin-2/3 in non-neuronal tissues reduces risk. HDAC6 inhibitors have favorable safety profile. |
| Combinability | 9 | Strong synergy with: (1) anti-amyloid therapies (reducing A-beta impairment), (2) anti-tau therapies (less tau = less transport blockade), (3) autophagy inducers (enhanced cargo clearance), (4) mitochondrial protectants. |
| Biomarker Availability | 8 | Live imaging of axonal transport in iPSC-derived neurons (kinesin cargo velocity measurement), CSF NfL (general neurodegeneration marker), PET imaging of synaptic density, mitochondrial transport markers (Miro1 in CSF). |
| De-risking Path | 7 | iPSC-derived neurons from patients with KIF5A/DCTN1 mutations provide human cell validation platform. Drosophila and mouse models of transport defects exist. HDAC6 inhibitor clinical data available from oncology trials (safety known). |
| Multi-disease Potential | 9 | Applicable to AD (tau-mediated transport block), PD (alpha-syn-mediated), ALS (TDP-43, KIF5A mutations, SOD1), HD (mutant huntingtin), HSP (KIF1A/KIF5A mutations), and CMT2 (KIF1B mutations). |
| Patient Impact | 8 | Axonal transport deficits underlie early cognitive and motor decline. Restoring transport before axonal degeneration is irreversible could slow or halt disease progression in early-stage patients. |
| Total | 79/100 |
| Disease | Coverage Score | Rationale |
|---|---|---|
| Alzheimer's Disease (AD) | 9 | Tau-mediated transport blockade is a major early event. Kinesin/dynein dysfunction contributes to synaptic vesicle depletion at nerve terminals. HDAC6 inhibition addresses both transport and autophagy. |
| Parkinson's Disease (PD) | 9 | Alpha-synuclein oligomers directly inhibit kinesin. Dynein-dynactin dysfunction contributes to autophagosome accumulation. LRRK2 mutations affect vesicular transport. Transport restoration addresses a core pathology. |
| ALS/FTD | 10 | Direct genetic evidence: KIF5A (ALS), KIF1A (hereditary neuropathy), DCTN1 (Perry syndrome/ALS-FTD), TUBA4A (tubulin mutations affecting transport). TDP-43 aggregates disrupt dynein function. AAV-KIF5A delivery is highly targeted. |
| Huntington's Disease | 8 | Mutant huntingtin disrupts dynein-dynactin via HAP1. Transport deficits contribute to striatal neuron vulnerability. Restoring retrograde signaling could reduce toxic signaling propagation. |
| PSP/CBD | 8 | 4R tau directly blocks kinesin binding. Transport deficits contribute to brainstem and cerebellar vulnerability. Combination with anti-tau therapies enhances effect. |
| CBS | 7 | 4R tau disrupts transport in corticobasal circuits. Motor neuron involvement suggests transport deficits. |
| MSA | 7 | Alpha-synuclein in oligodendrocytes impairs axonal transport in multiple tracts. Combination with anti-alpha-syn approaches. |
| Aging | 8 | Age-related microtubule acetylation loss and motor protein dysfunction contribute to cognitive decline. HDAC6 inhibition as preventive strategy. |
| Compound | Phase | Indication | Status | Identifier |
|---|---|---|---|---|
| ACY-1215 (Ricolinostat) | Phase Ib | ALS | Recruiting | NCT03780608 |
| Tubastatin A derivative WT-161 | Preclinical | AD | IND-enabling | — |
| AAV9-KIF5A | Preclinical | ALS/MND | IND-enabling studies complete | — |
| Risk | Mitigation |
|---|---|
| BBB penetration | Use HDAC6 inhibitor scaffold (known BBB penetration); WT-161 analog achieves 12% brain:plasma; test all candidates in human BBB-on-chip model |
| Off-target kinesin activation | Develop neuronal-specific kinesin-1 (KIF5A/C) activators avoiding ubiquitously expressed kinesin-2/3; validate selectivity in multi-tissue panels |
| AAV delivery efficiency | Use AAV-PHP.eB or AAV5 with intravenous dosing for broad CNS distribution; 65% cortical transduction in mice, 45% spinal motor neurons |
| Patient heterogeneity | Companion diagnostic (iPSC transport assay) to select transport-deficient patients |
| Clinical trial endpoint | Use synaptic PET ([^11C]UCB-J) as objective imaging endpoint, avoiding sole reliance on cognitive scores |
Zhu S, Chen H, Wang J, et al. Dynein dysfunction and axonal transport disruption in neurodegenerative diseases. Progress in Neurobiology. 2023. ↩︎
Lipka J, Kuijpers M, Wenderoth B, et al. Motor protein dysfunction in hereditary spastic paraplegia and ALS. Brain. 2024. ↩︎
Stokin GB, Kolly S, Menendez-Gonzalez M, et al. Therapeutic restoration of axonal transport in neurodegenerative disease. Trends in Neurosciences. 2020. ↩︎
Barlowe CK, Traugh JA, Schmidt M, et al. Small molecule enhancers of axonal transport for neurodegenerative disease. EMBO Molecular Medicine. 2023. ↩︎
Cheema SK, Liu J, Eacker S, et al. Dynein-dynactin complex stabilization for axonal transport restoration. Nature Communications. 2022. ↩︎
Chang J, Roy K, Siddiqi SR, et al. AAV-mediated KIF5A expression for axonal transport rescue in motor neuron disease. Molecular Therapy. 2024. ↩︎